LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Начало・Списък с акции・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Затворен

СекторЗдравеопазване

3.93 0.26

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.9

Максимум

4.01

Ключови измерители
By Trading Economics
Приходи	3.4M -9.8M
Служители	34
EBITDA	3.5M -9.8M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+408.91% upside

Дивиденти
By Dow Jones
Следващи печалби	12.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	124M 389M
Предишно отваряне	3.67
Предишно затваряне	3.93

Настроения в новините

By Acuity

10%

90%

6 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

8.275 / 9.312 Подкрепа & съпротива

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.02.2026 г., 22:17 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP 1st Half Net Profit, Dividend Rise; Signs $4.3 Billion Silver Streaming Deal

16.02.2026 г., 23:48 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

16.02.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Decline; Prime Minister Takaichi's Policy Steps in Focus -- Market Talk

16.02.2026 г., 23:23 ч. UTC

Придобивния, сливания и поглъщания

BHP Shares Up 7.0% After Silver Streaming Deal, Profit Beat

16.02.2026 г., 23:20 ч. UTC

Придобивния, сливания и поглъщания

BHP Exploring Other Infrastructure Deals as It Chases $10 Billion Target - Interview

16.02.2026 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Brokers Value BHP's Total Stake in Antamina Around $4.5 Billion

16.02.2026 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Has Desalination, Other Power Assets on Which Deals Could Be Considered

16.02.2026 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Wants to Make Sure It Does Not Give Up Any Strategic, Operational Control of Assets

16.02.2026 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Will Allocate Cash From Asset Deals to Growth, Shareholder Returns

16.02.2026 г., 22:47 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Won't Put Deadline on $10 Billion Cash Unlock Target

16.02.2026 г., 22:47 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Bar Very High For Asset Deals

16.02.2026 г., 22:47 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Sees 'Quite a Lot of Opportunities' in Potential Infrastructure Deals

16.02.2026 г., 22:35 ч. UTC

Пазарно говорене

Australian Jobs Data Could Confirm Market Too Tight -- Market Talk

16.02.2026 г., 22:02 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP 1H Net Profit, Dividend Rise; Signs $4.3 Billion Silver Streaming Deal

16.02.2026 г., 21:48 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP: Optimistic That Economic Backdrop Supportive For Key Commodities

16.02.2026 г., 21:48 ч. UTC

Придобивния, сливания и поглъщания

Wheaton Precious Metals: Acquisition Immediately Increases Production and Cash Flow Profile

16.02.2026 г., 21:48 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP: China's Economy Resilient; India Continues to Outperform

16.02.2026 г., 21:47 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP: Streaming, WAIO Power Deals Unlock Over $6 Billion of Cash Combined

16.02.2026 г., 21:47 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP: Sees Potential to Unlock Up to $10 Billion From Portfolio, Asset Management

16.02.2026 г., 21:47 ч. UTC

Придобивния, сливания и поглъщания

Wheaton Precious Metals to Have Combined 67.5% of All the Silver Produced From Antamina, Up From 33.75% Currently

16.02.2026 г., 21:46 ч. UTC

Придобивния, сливания и поглъщания

Wheaton Precious Metals: Upfront Payment to Be Funded Through Combination of Existing Liquidity and New Financing

16.02.2026 г., 21:46 ч. UTC

Придобивния, сливания и поглъщания

Wheaton Precious Metals Will Pay BHP Total Upfront Cash Consideration of $4.3B on Closing

16.02.2026 г., 21:46 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP Interim Dividend Represents 60% Payout Ratio

16.02.2026 г., 21:46 ч. UTC

Придобивния, сливания и поглъщания

Wheaton Precious Metals in Definitive Precious Metals Purchase Agreement BHP Subsidiary for Its 33.75% Portion of Silver Produced at Antamina Mine in Peru

16.02.2026 г., 21:45 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP: Copper Contributed 51% of 1H Underlying Ebitda

16.02.2026 г., 21:43 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP Net Debt $14.69 Billion at Dec. 31, Up 25% On-Year

16.02.2026 г., 21:43 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP 1H Net Operating Cash Flow $9.37 Billion, Up 13% On-Year

16.02.2026 г., 21:42 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP 1H Underlying Ebitda $15.46 Billion, Up 25% On-Year

16.02.2026 г., 21:42 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP Was Expected to Record Underlying Profit of $6.03 Billion According to Visible Alpha

16.02.2026 г., 21:41 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP 1H Underlying Profit $6.20 Billion, Up 22% On-Year

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

408.91% нагоре

12-месечна прогноза

Среден 20 USD 408.91%

Висок 20 USD

Нисък 20 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Anavex Life Sciences Corp през последните 3 месеца.

Техническа оценка

By Trading Central

8.275 / 9.312Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

6 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.